Physician profile
Adam D Botwinick
NPI 1366734097
$3,886.51
in general payments reported to CMS, 2019-2025
24 companies · $591 in 2025
The $591 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $643 · 2020: $388 · 2021: $543 · 2022: $415 · 2023: $389 · 2024: $919 · 2025: $591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,898.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,897.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $420.82 | 2019-2021 | |
| Oyster Point Pharma, INC. | $418.26 | 2022-2025 | Tyrvaya, Ryzumvi |
| Allergan, INC. | $386.29 | 2019-2021 | |
| Alcon Vision LLC | $305.67 | 2022-2025 | Simbrinza, Clareon |
| Kala Pharmaceuticals, INC. | $303.26 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $237.17 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Biotissue Holdings INC. | $220.33 | 2019-2024 | |
| Tarsus Pharmaceuticals, INC. | $191.76 | 2024-2025 | Xdemvy |
| Harrow Eye, LLC | $187.70 | 2024-2025 | Vevye |
| Abbvie INC. | $168.20 | 2022-2025 | Durysta |
| Glaukos Corporation | $154.63 | 2019-2024 | Idose |
| Dompe US, INC. | $138.72 | 2022-2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $131.32 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $123.70 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $102.44 | 2020-2024 | Cequa |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $96.68 | 2023-2025 | Kahook Dual Blade, Ahmed Glaucoma Valve, Streamline |
| Horizon Therapeutics Plc | $60.63 | 2023 | Tepezza |
| Sight Sciences, INC. | $57.60 | 2022-2024 | Omni Surgical System |
| Mallinckrodt Hospital Products INC. | $45.23 | 2024 | Acthar |
| Thea Pharma INC. | $43.69 | 2024-2025 | Iyuzeh |
| Amgen INC. | $39.92 | 2024 | Tepezza |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Springworks Therapeutics, INC. | $19.14 | 2025 | Gomekli |
| Eyevance Pharmaceuticals LLC | $13.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Botwinick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.